Skip Navigation

Adalvo Leads the Way in Diabetes Care with Unique Injectable and Oral Portfolio

04 October 2023

Adalvo is thrilled to be making remarkable strides in the world of diabetic care. With an unwavering commitment to patient well-being, Adalvo proudly stands alone as the sole B2B company capable of offering a comprehensive diabetes product line, encompassing both injectables and oral.

Diabetes is a global healthcare challenge, and Adalvo is at the forefront, addressing this pressing issue with a holistic approach. 

We have become a one-stop-shop solution for partners looking for diabetes products, offering a basket of seven dossiers, at a combined global market size of $54BN, with a CAGR of 26% (according to IQVIA).

Our dossiers include, but are not limited to:

Adalvo will continue to grow their portfolio offerings in this domain, further highlighting our ability to offer differentiated, value-added products to our partners.

Partner Up Now!

At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward. - Head of Global BD&L - LATAM (exc. Brazil) - South Europe – Central & Eastern Europe, Russia & CIS North Europe, APAC, MENA & Israel - Central and Western Europe – Europe – UK/Ireland, North America & South Africa

Click on your preferred Business Partner and get in touch today!